通过调节PABPC1介导的mRNA稳定,LncRNA PRBC诱导自以促进乳腺癌的进展
Yiran Liang1, Bing Chen2, Fanchao Xu1
1Department of Breast Surgery, General Surgery, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, P.R. China.
Oncogene
|February 17, 2024
概括
一种新的长非编码RNA, lncRNA PRBC,通过增强自和影响microRNA活动来促进乳腺癌的进展. 它可以作为乳腺癌的治疗目标和预后预测器.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 乳腺癌是全球女性死亡的主要原因之一.
- 长非编码RNAs (lncRNAs) 与各种癌症有关,但它们在乳腺癌中的作用尚未完全理解.
- 识别新的分子参与者对于了解乳腺癌进展至关重要.
研究的目的:
- 识别和描述涉及乳腺癌的新型长非编码RNA (lncRNAs).
- 阐明新发现的lncRNA,lncRNA PRBC在乳腺癌进展中的功能作用和分子机制.
- 评估lncRNAPRBC作为潜在的预后生物标志物和乳腺癌的治疗标.
主要方法:
- 定量实时PCR用于评估乳腺癌组织中的lncRNA表达.
- 功能性测试 (例如,自,细胞增殖,迁移) 来确定lncRNA PRBC的作用.
- RNA免疫沉 (RIP) 试验用于研究 lncRNA-蛋白相互作用.
- 西方斑点和免疫光检测分析蛋白质定位和功能.
主要成果:
- 一种名为lncRNA PRBC (NONHSAT137675) 的新型lncRNA被发现在乳腺癌组织中显著上调.
- lncRNA PRBC通过增强自和影响下游微RNA (miRNA) 活动来促进乳腺癌的进展.
- 在机制上,lncRNA PRBC与PABPC1相互作用,促进其细胞质转位,并在RNA诱导沉默复合体 (RISC) 中增强PABPC1-AGO2相互作用.
- Knockdown 的 lncRNA PRBC 抑制了乳腺癌细胞的恶性行为,而 PABPC1 的过度表达可以逆转这些影响.
结论:
- lncRNA PRBC 在乳腺癌恶性进展中起着至关重要的作用.
- 该机制涉及诱导PABPC1的细胞质转位,该转位调节下游miRNA功能.
- lncRNA PRBC代表了乳腺癌患者的有前途的治疗标和预后预测器.
相关概念视频
02:39lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
02:23Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
02:55The Nucleolus
8.8K
The nucleolus is the most prominent substructure of the nucleus. When it was first discovered, it was considered to be an isolated organelle that forms fibrils and granules. In 1931, the relationship between the nucleolus and chromosomes was first described by Heitz. He observed that the appearance and size of nucleolus varies depending on the stage of the cell cycle. He also noticed constricted regions on different chromosomes clustered together at definite cell cycle stages. These regions,...
8.8K
01:31The Intrinsic Apoptotic Pathway
6.5K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.5K
01:22PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K